-+ 0.00%
-+ 0.00%
-+ 0.00%

Xilio Therapeutics To Present Initial Phase 1C Dose Escalation Data For Vilastobart At SITC Annual Meeting; Report Phase 2 Data In Microsatellite Stable Colorectal Cancer For Vilastobart In Combination With Atezolizumab In Q4; Report Phase 1 Data For XTX301 In Q4

Benzinga·11/07/2024 14:13:41
Listen to the news

Will present initial Phase 1C dose escalation data for vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab, in a late-breaker poster presentation at the SITC Annual Meeting

Expect to report initial Phase 2 data in microsatellite stable colorectal cancer (MSS CRC) for vilastobart in combination with atezolizumab in the fourth quarter of 2024

Expect to report Phase 1 data for XTX301, a tumor-activated IL-12, in the fourth quarter of 2024